IGC
IGC Pharma, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
IGC Pharma, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
No changes.
No changes.
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
No thesis.
Largest filed tie
0
filed ties
—
No peers for IGC Pharma, Inc. yet.
No peers for IGC Pharma, Inc. yet.
Annual filing, covered
10-K parsed · Jun 27 '25
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Jun 27 '25
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
—
IGC Pharma, Inc.
0.20
+0.01 · +7.46%
| Manager | Value | % base | |
|---|---|---|---|
| Geodeindex-like | $239,229 | 16.89% | −15.72% |
| Vanguardindex-like | $221,657 | 15.65% | +13.43% |
| BlackRockindex-like | $191,433 | 13.52% | 0.00% |
| AdvisorShares | $184,547 | 13.03% | new |
| Citadel | $118,950 | 8.40% | new |
| Manager | Value | % base | |
|---|---|---|---|
| Geodeindex-like | $239,229 | 16.89% | −15.72% |
| Vanguardindex-like | $221,657 | 15.65% | +13.43% |
| BlackRockindex-like | $191,433 | 13.52% | 0.00% |
| AdvisorShares | $184,547 | 13.03% | new |
| Citadel | $118,950 | 8.40% | new |
Expected move
No implied move.